1. Introduction {#sec1}
===============

Host factors required for the replication of multiple viruses provide for a good target for the development of broad-spectrum antiviral drugs. Recent advances in the development of novel antiviral therapies have taken advantage of similarities in viral replication strategies by identifying and targeting host cell pathways required for viral replication that are common to *Flaviviridae* or other viruses. One such pathway is the host N-linked glycosylation pathway, which has been shown to be required for the replication of multiple enveloped viruses ([@bib165]). The aim of this review is to highlight the anti-*Flaviviridae* activity of iminosugars, a promising class of host-targeted antivirals (HTAVs) that can interfere with the host's N-linked glycosylation pathway by inhibiting α-glucosidases in the endoplasmic reticulum (ER).

2. N-linked glycosylation {#sec2}
=========================

Protein glycosylation is an essential post-translational modification required for the proper folding and function of glycoproteins and plays a key role in many cellular processes, including protein-protein and cell-cell interactions. N-linked glycosylation, the most common form of protein glycosylation, is catalyzed at the luminal face of the ER. The oligosaccharyltransferase complex (OST) co-translationally attaches the preformed N-linked glycan core, Glc~3~Man~9~GlcNAc~2~, to an asparagine residue within the sequence asparagine-X-serine/threonine (N-X-S/T) of the target peptide, where "X" represents any amino acid residue, except proline. Several factors can contribute to the glycosylation efficiency of N-X-S/T motifs, including the ability of the OST complex to access the sequon as well as the sequence content ([@bib74]; [@bib101]). Glycosylation efficiency is typically higher when the target sequence contains a threonine rather than a serine ([@bib74]).

Processing of the attached N-linked oligosaccharide begins with sequential cleavage of terminal glucose residues by the ER α-glucosidases I and II. The distal glucose residue (α1,2-glucose) is cleaved by α-glucosidase I to generate Glc~2~Man~9~GlcNAc~2~ ([@bib80]), which can then associate with the ER membrane-bound lectin, malectin, or be further processed by α-glucosidase II ([@bib142]). The ER α-glucosidase II enzyme is responsible for consecutively cleaving the second and third glucose residues to generate Man~9~GlcNAc~2~ ([@bib80]). However, prior to cleavage of the third glucose residue, the chaperone proteins, calnexin and calreticulin, can bind to the monoglucosidated glycan and assist with folding and proper disulfide bond formation through interaction with a protein disulfide isomerase ([@bib64]; [@bib110]). Once the third glucose residue is cleaved, proteins that are not properly folded can be transiently reglycosylated by UDP glucotransferase 1 to prevent further processing and return to the calnexin/calreticulin cycle. Proteins may progress through a series of reglycosylation, refolding, and processing steps until properly folded and sent to the Golgi apparatus for further processing. If proper folding is not achieved, the ER enzyme mannosidase I may remove the mannose residues from the oligosaccharide to prevent reglycosylation and reprocessing through the calnexin cycle, and the protein may be targeted for degradation by the ER-associated degradation pathway ([@bib5]).

The ER glycosylation machinery is not only required for host protein glycosylation, it is also critical for the lifecycle of diverse viruses. N-linked glycosylation is a necessary component for the replication of many viruses as it is required for the proper folding, trafficking, and/or receptor binding of some viral proteins ([@bib165]; [@bib176]). Because viruses do not possess their own glycosylation machinery, they rely on host-cell machinery for these processes. Viral dependency on this pathway was demonstrated in a case study of two patients with MOGS-CDG, a rare congenital disorder caused by absent expression of α-glucosidase I and a lack of N-linked glycan processing in the ER ([@bib138]). Although these patients had hypogammaglobulinemia and other complications, they also had no documented history of viral illness. These patients had no immune recognition against childhood vaccinations consisting of live virus vaccines directed against measles, mumps, rubella, and varicella viruses, which contain glycosylated envelopes, but had normal antibody responses when vaccinated with nonreplicating infectious agents presenting proteins, polysaccharides, and other immunogens, including the diphtheria-tetanus-acellular pertussis, hepatitis B, 23-valent pneumococcal polysaccharide, and conjugated *Haemophilus influenzae* type B vaccines. Additionally, cells isolated from these patients had increased resistance to infection by the glycosylation-dependent human immunodeficiency virus (HIV) and influenza A virus *in vitro,* but not to the nonenveloped viruses, adenovirus or poliovirus 1, confirming this pathway has an essential role in the replication of certain viruses.

*3*. *Flaviviridae* replication and the role of the host glycosylation pathway {#sec3}
==============================================================================

3.1. Genomic organization and replication strategies employed by *Flaviviridae* {#sec3.1}
-------------------------------------------------------------------------------

Although there are distinct differences in the mode of transmission, tissue tropism, and course of infection between different members of the *Flaviviridae* family ([Supplemental Table 1](#appsec1){ref-type="sec"}), all viruses in this family have similar replication cycles and genomic organization. The *Flaviviridae* RNA genome ranges from 9,000 -- 13,000 bases containing one open reading frame that encodes for a single polyprotein ([@bib145]). After the virus is internalized through receptor-mediated endocytosis, the viral RNA genome is released into the cytoplasm where it is translated into the polyprotein, which is processed by viral and host-cell proteases to produce ∼ 3 -- 4 structural and ∼ 6 -- 8 non-structural (NS) proteins, depending on the virus. RNA replication occurs in membrane-associated viral replication organelles that are derived from the endoplasmic reticulum (ER) ([@bib117]; [@bib122]). Immature viral particles are assembled on the surface of the ER and are transported through the trans-Golgi network where they are further processed to produce mature virus particles that are subsequently released from the cell by exocytosis.

Structural proteins are derived from the amino terminus end of the polyprotein to allow the virus to maximize production of these proteins, while the NS proteins are derived from the carboxyl-terminal end. NS proteins are involved with proteolysis, viral assembly, regulation of host immunity, and RNA replication, and include sequences that are characteristic of an RNA-dependent RNA polymerase, serine protease, and RNA helicase ([@bib18]; [@bib44]; [@bib145]; [@bib187]). Pestiviruses, pegiviruses, and hepaciviruses also contain an additional P7/P13 protein that is believed to be important for viral maturation that is not expressed by members of the *flavivirus* genus. Structural proteins, which are required to form progeny virus particles, include 2 or 3 membrane-associated glycoproteins that differ slightly between genera. Hepaciviruses, flaviviruses, and pestiviruses also contain a structural basic capsid protein (C) which assembles to form the nucleocapsid that encases the viral genetic material.

The membrane-associated glycoproteins contain a variable number of potential N-linked glycosylation sites depending on the virus and the protein. During viral replication, N-linked glycans are added to the target N-X-S/T motifs in viral glycoproteins and processed by the host ER glycan processing and protein folding machinery.

3.2. Flavivirus replication and protein glycosylation {#sec3.2}
-----------------------------------------------------

Flavivirus structural proteins include the C protein, precursor membrane glycoprotein (prM), and envelope (E) protein, although only membrane-associated E proteins are exposed on the surface of mature particles. The E protein is glycosylated and co-translationally processed in the ER lumen where it heterodimerizes with prM, which can function as a chaperone to stabilize E proteins ([@bib67]; [@bib186]) and ensure proper protein folding ([@bib86]; [@bib91]; [@bib176]; [@bib178]). The prM-E heterodimers further oligomerize ([@bib79]; [@bib186]) and assemble into immature, noninfectious virions containing nucleocapsid protein complexed with viral RNA ([@bib91]; [@bib92]; [@bib98]). The immature virions are translocated to the Golgi complex where the low pH environment promotes reorganization of the prM-E heterodimers, allowing for the host protease, furin, to cleave prM to the mature membrane protein (M) ([@bib44]; [@bib86]; [@bib149]; [@bib179]). This results in the formation of head-to-tail E homodimers and the generation of mature infectious particles that are eventually released from the cell by exocytosis ([@bib81]; [@bib113]; [@bib152]). The DENV prM/M protein contains an N-linked glycosylation site at N69, and may contain other sites at additional locations (N7, N31, N52) ([@bib33]). The ability of prM to act as a chaperone for E protein is thought to be dependent on glycosylation of prM ([@bib33]; [@bib67]). Removal of the N-linked glycosylation site from the prM protein of JEV and certain WNV strains can significantly decrease the amount of newly formed virus particles secreted from mammalian cells ([@bib61]; [@bib78]; [@bib182]).

Several potential N-linked glycosylation motifs have also been identified in the flavivirus E glycoprotein ([@bib34]; [@bib52]; [@bib60]; [@bib68]; [@bib71]; [@bib113]; [@bib186]). The DENV E protein is glycosylated at two asparagines, N67 and N153 ([@bib22]; [@bib59]; [@bib71]). N153 is a conserved glycosylation site in most *Flaviviridae* (present as N154 in some viruses), whereas N67 is unique to DENV. Glycosylation of N67 is thought to mediate the interaction between the virus and the host cell receptor DC-SIGN and is required for assembly and egress of DENV ([@bib19]; [@bib111]; [@bib130]).

The E protein of most flaviviruses, aside from DENV, contains only the single, conserved N153/154 glycosylation site. N-linked glycosylation of the flavivirus E protein has been associated with pH sensitivity, neurovirulence, infectivity, and virus secretion ([@bib8]; [@bib19]; [@bib58]; [@bib61]; [@bib76]; [@bib84]; [@bib85]; [@bib111]; [@bib112]; [@bib159]). Deletion of the N153/154 glycosylation site results in decreased secretion of DENV ([@bib84]), TBEV ([@bib55]; [@bib177]), ZIKV ([@bib112]), and WNV ([@bib61]) from mammalian cells, and attenuation of ZIKV in mouse models of disease ([@bib49]). Despite the importance of this glycosylation site for many flaviviruses, not all flavivirus E proteins are N-glycosylated. For WNV, there is a correlation between viruses that contain the E protein glycosylation site and those that are responsible for many of the major outbreaks of human disease ([@bib61]).

The flavivirus genome also encodes seven NS proteins: NS1, NS2A/B, NS3, NS4A, 2K, NS4B, and NS5 ([@bib3]; [@bib89]; [@bib180]; [@bib187]). NS1 contains two potential N-glycosylation sites (N130 and N207) that are conserved in flaviviruses ([@bib48]; [@bib132]; [@bib172]), in addition to less conserved sites (e.g. N175 in WNV) ([@bib1]). NS1 glycosylation is necessary for proper replication and virulence of DENV, although the mechanism of how NS1 glycosylation is involved in these processes is not well understood ([@bib114]; [@bib148]).

3.3. HCV replication and protein glycosylation {#sec3.3}
----------------------------------------------

HCV structural proteins include the C protein and two envelope proteins, E1 and E2, which are dependent on each other for proper protein folding ([@bib16]; [@bib32]). E1 and E2 contain 9 -- 11 and 4 -- 5 highly conserved glycosylation sites, respectively, depending on the viral genotype ([@bib54]). Following glycosylation, E1 and E2 can form noncovalently-bound heterodimers that interact with the ER chaperone protein, calnexin, to assist with productive folding of the proteins ([@bib9]; [@bib27]; [@bib31]; [@bib120]). Alternatively, the glycoproteins can interact with calreticulin and form disulfide bridges, resulting in the production of misfolded protein aggregates ([@bib9]; [@bib27]; [@bib31]; [@bib36]; [@bib120]) Formation of E1/E2 heterodimers is important for viral fusion, entry, and secretion ([@bib88]). Mutation studies demonstrated that specific glycosylation sites in the HCV envelope proteins are important for the correct folding and heterodimerization of E1 and E2, including N1 and N4 in E1, and N1, N8 and N10 in E2 ([@bib51]; [@bib53]; [@bib65]). Glycosylation of several sites in E2 is also believed to contribute to immune evasion ([@bib65]).

3.4. Evidence of *Flaviviridae* dependency on host ER α-glucosidases {#sec3.4}
--------------------------------------------------------------------

Considering the important role N-linked glycosylation can have in the folding and function of *Flaviviridae* glycoproteins, it is likely that impeding this pathway could lead to detrimental effects on viral replication. Consistent with this concept, the ER α-glucosidases have been confirmed as antiviral targets for multiple viruses in the *Flaviviridae* family, including HCV, DENV, YFV, and ZIKV. Downregulation of either α-glucosidase enzymes in Huh7.5 cells by shRNA resulted in a 5-fold reduction in the production of HCV particles without impacting cell growth or viability ([@bib133]). In a separate study, CRISPR/Cas9 technology was used to generate Huh7.5 cell lines lacking expression of α-glucosidase I or α-glucosidase II, and the impact on viral replication and particle secretion was measured following infection with DENV, YFV, or ZIKV ([@bib96]). A significant reduction in intracellular viral RNA and virus secretion (∼10 -- 1000-fold) was observed for DENV and YFV in α-glucosidase I and II knockout Huh7.5 cells compared to control parental cells. Expression of α-glucosidase II was not required for the replication of ZIKV; however, loss of α-glucosidase 1 expression reduced ZIKV secretion by greater than 10-fold. These studies provide evidence that the ER α-glucosidases have a functional role in the replication of several virulent *Flaviviridae* pathogens.

4. Iminosugars {#sec4}
==============

The required involvement of the host's ER glycosylation machinery for replication of diverse viruses makes it a key target for broad-spectrum HTAV therapies. Iminosugars are sugar mimetics that can function as competitive inhibitors of a variety of glycosidase and glycosyltransferase enzymes that interact with sugar substrates. Certain iminosugars are known to inhibit the ER glycosylation pathway by targeting and inhibiting α-glucosidase I and α-glucosidase II and comprise the largest class of α-glucosidase inhibitors currently in development ([@bib146]). Perturbing ER α-glucosidase function can prevent the enzymes from removing terminal glucose residues on N-linked glycans, thereby inhibiting the interaction with the calnexin/calreticulin chaperone proteins and proper folding of some viral glycoproteins. This can ultimately lead to the activation of the cellular unfolded protein response, which can detect the misfolded viral proteins and send them for degradation, resulting in decreased production of virions. Alternatively, it is possible that some misfolded viral glycoproteins may escape detection and incorporate into viral particles, greatly reducing their infectivity (Fischer et al., 2006).

The naturally occurring compounds 1-deoxynojirimycin (DNJ) and castanospermine (CAST) were some of the first iminosugars identified to have antiviral properties. Medicinal chemistry strategies to design derivatives of these iminosugars have led to the development of compounds with increased activity and decreased associated cytotoxicity. Numerous analogs and derivatives of DNJ and other iminosugars have been evaluated for antiviral activity against a diverse range of enveloped viruses, including members of the *Flaviviridae* family ([Figure 1](#fig1){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}, [Figure 5](#fig5){ref-type="fig"} ) and Ebola, Marburg, influenza A and B, herpes simplex, hepatitis B, Sindbis, Semliki Forest, chikungunya, measles, Newcastle disease, severe acute respiratory syndrome, Lassa, Junín, Rift Valley fever, vesicular stomatitis, and human immunodeficiency viruses ([@bib23]; [@bib109]).Figure 1Bicyclic iminosugars evaluated for activity against members of the *Flaviviridae* family. Structures for bicyclic iminosugars that have been tested for activity *in vitro* and *in vivo* against members of the *Flaviviridae* family, both of which have advanced to in clinical trials as potential HTAVs to combat *Flaviviridae* infections.Figure 1Figure 2DNJ derivatives evaluated *in vitro* for activity against a single member of the *Flaviviridae* family. Structures for monocyclic glucose-mimicking iminosugars that have been tested for activity *in vitro* against a single virus in the *Flaviviridae* family.Figure 2Figure 3DNJ derivatives evaluated *in vitro* for activity against multiple members of the *Flaviviridae* family. Structures for monocyclic glucose-mimicking iminosugars that have been tested for activity *in vitro* against two or more members of the *Flaviviridae* family.Figure 3Figure 4DNJ derivatives evaluated *in vitro* and *in vivo* for activity against members of the *Flaviviridae* family. Structures for monocyclic glucose-mimicking iminosugars that have been tested for activity against *Flaviviridae in vitro* and in animal models of disease, or that have advanced to clinical development for *Flaviviridae* infections. .Figure 4Figure 5DGJ and other non-glucose-mimicking iminosugars evaluated *in vitro* or *in vivo* for activity against members of the *Flaviviridae* family. Structures for iminosugars containing headgroups that mimic galactose (DGJ and DGJ-derivatives) or mannose (DMJ) that have been tested for activity against *Flaviviridae in vitro* or in animal models of disease.Figure 5

Although iminosugars are not currently approved for use as antiviral therapies, they have a good safety profile and a long history of use in humans. Several iminosugars are approved by the Food and Drug Administration (FDA) for other indications which require long-term treatment. The N-alkylated DNJ derivative, N-butyl-deoxynojirimycin (*N*B-DNJ/Miglustat/Zavesca®), is a glucosylceramide synthase enzyme inhibitor approved for use to treat adult patients with type 1 Gaucher's disease, a lysosomal storage disorder that results from impaired break down of glucocerebroside due to decreased production of the enzyme, glucocerebrosidase. Migalastat (Galafold^TM^) is approved for the treatment of another type of genetic lysosomal storage disorder, Fabry disease, which is caused increased levels of globotriaosylceramide due to a deficiency in the production of the enzyme, alpha-galactosidase A. An FDA-approved DNJ derivative, N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099/Miglitol/Glyset®), is used to help control type 2 diabetes by targeting an α-glucosidase in the small intestines to prevent the breakdown of large carbohydrates into glucose. Acarbose (PRECOSE®) is similarly approved in the United States and other countries for the treatment of diabetes, as is voglibose (Voglib) in Japan. Several of these medications have been used in human patients for over 25 years and are considered safe treatment options for the intended indications. The clinical long-term use of iminosugars to treat these chronic diseases demonstrates the safety of this class of compounds and supports the further development of iminosugars for other indications, such as the treatment or prevention of certain viral infections. Although treatment of viral infections would require systemic delivery, for many viruses it would consist of a much shorter duration of treatment than for chronic indications which is expected to limit the impact on host physiology. One of the practical challenges that needs to be considered when developing novel iminosugars for antiviral indications is the interaction between iminosugars and intestinal glucosidases, which is associated with undesired gastrointestinal side-effects. This can potentially be overcome by designing selective ER α-glucosidase inhibitors with reduced activity against the gastrointestinal enzymes and ensuring good bioavailability to minimize inhibition of intestinal glucosidases. It should be pointed out that gastrointestinal distress caused by long-term *N*B-DNJ (Zavesca®) use can be mitigated by changing dietary habits, such as reducing carbohydrate load with oral administration of the drug.

*5*. *In vitro* efficacy and mechanism of anti-*Flaviviridae* activity {#sec5}
======================================================================

A substantial amount of research has been performed in the past 20 years evaluating the activity of iminosugars against members of the *Flaviviridae* family ([Figure 1](#fig1){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}, [Figure 5](#fig5){ref-type="fig"}). Data from published studies assessing the antiviral effect of iminosugars against *Flaviviridae* in cell culture are summarized in [Table 1](#tbl1){ref-type="table"} (bicyclic iminosugars), [Table 2](#tbl2){ref-type="table"} (monocyclic glucose-mimicking iminosugars), and [Table 3](#tbl3){ref-type="table"} (galactose-mimicking and other iminosugars). The details for each study are provided in [Supplemental Table 2](#appsec1){ref-type="sec"}.Table 1*In vitro* activity of bicyclic iminosugars against members of the *Flaviviridae* family. References are provided in [Figure 5](#fig5){ref-type="fig"} and details for each study are included in [Supplemental Table 2](#appsec1){ref-type="sec"}.Table 1Bicyclic IminosugarsCompound(s)VIRUSSummary of ResultsBVDVDENVJEVWNVYFVCastanospermine (CAST)XXXXX**DENV (1-4)** in multiple cell types: Reduced production of infective particles. IC~50~=1-85.7 μm. Resulted in altered prM glycosylation (**DENV-2** in BHK-21 cells) and impaired formation of prME heterodimers (**DENV-1** in Neuro 2a cells).\
**WNV** in BHK-21 cells: minimal to no inhibitory effect at up to 500 μM\
**YFV** in BHK-21 cells: 57% reduction at 50 μM\
**JEV** in PS cells: ≤10-fold reduction in virus titer\
**BVDV** in MDBK cells: IC~50~ = 5 -- 367 μM; additive activity when used in combination with *N*B-DNJCelgosivir (BuCast)XX**DENV-1** and **-2** in multiple cell types: EC~50~=0.06-51 μM. Blocked transport of NS1 and E proteins from ER to Golgi and resulted in defect in NS1 glycosylation in BHK-21 cells\
**DENV-3** and **-4** in BHK-21 cells: EC~50~=0.31-0.68 μM. **BVDV**: Additive or synergistic activity in MDBK cells when used in combination with ribavirin or IFN-α.[^1]Table 2*In vitro* activity of DNJ and DNJ derivatives against members of the *Flaviviridae* family. References are provided in [Figure 5](#fig5){ref-type="fig"} and details for each study are included in [Supplemental Table 2](#appsec1){ref-type="sec"}.Table 2Monocyclic Glucose-mimicking IminosugarsCompound(s)VIRUSSummary of ResultsBVDVDENVHCVGBV-BJEVKUNWNVYFVZIKV2-THO-DNJ (UV-12)X**DENV-2** in Vero cells: IC~50~=27.71 μM, CC~50~\>500 μMCM-9-78XX**DENV-2** in BHK-21 or A549 cells: EC~50~=1.5-6.75 μM, CC~50~ \>40 μM\
**HCV** chimera in Huh7.5 cells: EC~50~=52.5 μM, CC~50~\>500 μM; shift in electrophoresis mobility for E2 and E2-p7 proteinsCM-10-18 (DNJ Derivative 7)XXXAll viruses, multiple cell lines: EC~50~=1.1-27.2 μM, CC~50~\>100 μM. Synergistic antiviral activity against **DENV-2** in A549 cells when combined with ribavirin.1-Deoxynojirimycin (DNJ)XXXXXXLow activity against most viruses with reported EC~50~ and EC~90~ values typically \>100 μM. Low cytotoxicity (CC~50~s reported as \>500 to \>10,000 μM, depending on cell type and highest concentration tested).\
**DENV-1** in Neuro 2a cells: E protein misfolding and impaired formation of prME heterodimers\
Greater effect on **DENV-2** secretion (6 log PFU/mL reduction) at 100 μm/mL compared to **JEV** (∼0.6-1 log PFU/mL reduction) in PS cells\
No inhibitory effect observed against **KUN** in Vero cells at 100 μMIHVR11029; IHVR17028XX**BVDV** in MDBK cells and **DENV-2** in BHK-21 cells: EC~50~=0.3-1.3 μM, CC~50~\>500 μMIHVR19029XXXXVarious cell types: EC~50~=0.25-1.7 μM (**BVDV**, **DENV-2**) and 21.5-30 μM (**YFV**, **ZIKV**), CC~50~\>100-500 μM. Synergistic antiviral effect against **YFV** when used in combination with T-705.MON-DNJ (UV-4/UV-4B)X**DENV 1-4** in Vero cells: IC~50~=2.1-86.49 μM, CC~50~\>500-1,000 μM\
**DENV-2** in MDMs: IC~50~=3.09 μM, CC~50~=3,150 μMN-5-Oxaheptyl-DNJ (5-07); N-5-Oxahexyl-DNJ (5-06);\
N-5-Oxaoctyl-DNJ (5-08);\
N-6-Oxadecyl-DNJ (6-10);\
N-6-Oxanonyl-DNJ (6-09);\
N-6-Oxaocytyl-DNJ (6-08)XMDBK cells: 5-07 and 5-06, no antiviral activity (up to 100 μM); 5-08 and 6-10, minimal antiviral activity (up to 100 μM); 6-09 and 6-08, moderate antiviral activity (up to 100 μM) but not improved compared to *N*N-DNJ. Series not advanced. CC~50~\>300 μM for all compounds.N-7-Oxadecyl-DNJ (UV-3)XX**BVDV** in MDBK cells: IC~50~=17-80 μM, CC~50~\>5,000 μM, reduced secretion of viral RNA in MDBK cells.\
**DENV-2** in Vero cells: IC~50~=41 μM, CC~50~ = \>500 μMNAP DNJ (UV-5)XVero cells: IC~50~=2 μM, CC~50~=350 μM; MDMs: IC~50~=0.04 μM, CC~50~=300 μMNB-DNJ (UV-1)XXX**BVDV** in MDBK cells: Large range in IC~50~s (2.5 to \>200 μm), depending on MOI and assay readout. Infecting with lower MOI resulted in lower IC~50~ across assays; Dose dependent reduction in secretion of infectious virus particles that correlates with misfolding of viral glycoprotein E2; Synergistic when used in combination with IFN α-2b; Treatment of persistently infected MDBK cells in combination with IFN and RBV (containing 10 μM NB-DNJ) was sufficient to permanently eliminate virus after 9 passages following drug withdrawal.\
**HCV** chimera/replicon system: Dose dependent decrease in production of infectious particles in Huh7-Lunet and Huh7.5 cells; Reduced electrophoretic mobility of E1 and E2 glycoproteins. In Sf9 cells, E1 and E1 glycoproteins accumulated in ER, had reduced mobility shift, and interaction with calnexin was disrupted.\
**DENV-2**: IC~50~=6-10.6 μM, CC~50~\>100 μM (MDMs); IC~50~=162 μM, CC~50~\>500 μM (Vero cells)NN-DNJ (N-nonyl-DNJ/UV-2/DNJ Derivative 6)XXXXXX**BVDV** in MBDK cells: Range in IC50s depending on assay and publication, with most ranging between 3-115 μM, CC~50~s mostly \>100 uM\
**DENV-2** in multiple cell lines: IC~50~=1-9 μM, CC~50~=20-317 μM; interfered with prM, E, and NS1 protein interaction with calnexin in BHK-21 cells\
**HCV** in Huh7/Huh7.5/Huh7-Lunet cells: Multiple genotypes evaluated. Dose dependent decrease in production of infectious particles. Reduced electrophoretic mobility shift of E1 and E2 glycoproteins (JFH1 replicon system); inhibition of p7 function for most genotypes tested except for JFH-1/452 (genotype 3a) in which a lower inhibition of infectious particle secretion (only ∼40% reduction at 50 μm) and minimal reduction in p7 function were observed. In S*f*9 cells using HCV VLPs, E1 and E2 glycoproteins accumulated in ER and had reduced mobility shifts; VLPs produced had reduced binding to huh7 cells.\
HCV JFH-1 replicon: Additive effect on reduction of secreted infectious virus when used in combination with Rimantadine.\
**JEV** in BHK-21 cells: Dose dependent inhibition (2-3 log reduction at 100 μM), CC50 =150μM; interfered with transient interaction between viral proteins (prM, E, and NS1) and calnexin.\
**KUN** in Vero cells: secreted infectious virus titer reduced by 3.5 log at 100 μM\
**WNV** in BHK-21 cells: IC~50~\<4 μM, CC~50~=20-100 μMOSL-1 (N-Pentylcyclohexyl-DNJ); OSL-3XX**BVDV** in MDBK cells: IC~50~\<20 μM, CC~50~=∼200 μM\
**WNV** in BHK-21 cells: IC~50~=4-10 μM, dose dependent inhibition.OSL-2XMDBK cells: IC~50~\>70 μM, CC~50~\>300 μMOSL-12-31; OSL-12-51XMDBK cells: IC~50~ = ∼70 μM (OSL-12-31) or \>70 μM (OSL-1-51), CC~50~\>300 μMOSL-95iiXXXXAll viruses, various cell lines: IC~50~=2-28 μM (**WNV** \<4 μM), CC~50~\>40-500 μM\
**HCV** JC1 chimera in Huh7.5 cells: shift in electrophoresis mobility for E2 and E2-p7 proteinsPBDNJ0801XXBHK-21 cells: EC~50~=0.1 μM (**DENV-2**) or 4.75 μM (**WNV**), CC~50~=70-80 μMPBDNJ0802XHuh7.5 cells: EC~50~=3.5 μM, CC~50~\>500 μMPBDNJ0803;\
PBDNJ0804XXXBHK-21 cells: EC~50~=0.07-0.1 μM (**DENV-2**) and 1.5-3.5 μM (**WNV**), CC~50~=65-85 μM.\
**HCV** chimera in Huh7.5 cells: EC~50~=1.7-5.4 μM, CC~50~\>200 μM, electrophoretic mobility shift and degradation of E2 and E2-p7 proteins (PBDNJ0804)SP-169; SP-173XXX**BVDV** in MDBK cells, **DENV-2**/**WNV** in BHK-21 cells: IC~50~=3-5 μM, CC~50~\>100 μMToP-DNJX**DENV-2**: No inhibition observed in Huh7.5 cells (up to 50 μM), IC~50~=12.7 μM in MDMs.DNJ Derivatives 7 - 13XReduction in viral RNA and infectious virus secretion measured in MDBK cells.\
Derivative 7: no antiviral activity at up to 50 μM\
Derivatives 8 and 9: No reduction at 10 μM, 25-75% reduction at 50 μM, CC~50~\>250 μM\
Derivatives 10 and 11: ∼50% reduction at 10 μM, CC~50~≥200 μM\
Derivatives 12 and 13: ≥75% reduction at 10 μM, CC~50~=29-51 μMDNJ Derivatives: 1a, 1b; 2b, 2c, 2e, 2f, 2g, 2i, 2j; 3d, 3e, 3f, 3g, 3h, 3i, 3m, 30, 3u; 4d, 4e, 4f; 5a, 5bXSingle cycle virus yield reduction plaque assay using MDBK cells.\
Derivative 1 compounds: EC~50~=3-7.5 μM, CC~50~≥450 μM\
Derivative 2 compounds: EC~50~=0.3-1.8 μM, CC~50~≥150-500 μM\
Derivative 3 compounds: EC~50~=0.4-5.0 μM, CC~50~≥62-500 μM\
Derivative 4 compounds: EC~50~=3.5-24 μM, CC~50~=295-420 μM\
Derivative 5 compounds: EC~50~=11 μM (5a) and \>100 μM (5b), CC~50~\>500 μMDNJ Derivatives: 1c, 2a, 2d, 2h, 2k, 2l, 3a, 3b, 3c, 3j, 3k, 3l, 3n, 3p, 3q, 3r, 3s, 3t, 3v, 4a, 4b, 4c, 5dXX**BVDV** in MDBK cells and **DENV-2** in BHK-21 cells: Activity of individual compounds comparable against DENV and BVDV.\
Derivative 1 compounds: EC~50~=0.3-0.6 μM, CC~50~≥480 μM\
Derivative 2, 3, and 4 compounds: EC~50~=0.3-4 μM, CC~50~≥400 μM\
Derivative 5 compounds: EC~50~=0.9-47 μM, CC~50~\>500 μMSP-116; SP-150; SP-156; SP-159; SP-164; SP-165; SP-166; SP-168; SP-187XVirus yield reduction using MDBK cells:\
SP-165, SP-166, SP-187: IC~50~=3-12 μM, CC~50~≥400 μM\
SP-116, SP-150, SP-156, SP-159, SP-168: IC~50~=24-40 μM, CC~50~≥500 μM\
SP-164: IC~50~=150 μM, CC~50~\>1,000 μM[^2]Table 3*In vitro* activity of iminosugars containing headgroups that mimic galactose (DGJ and DGJ-derivatives) or mannose (DMJ) tested for activity against members of the *Flaviviridae* family. References are provided in [Figure 5](#fig5){ref-type="fig"} and details for each study are included in [Supplemental Table 2](#appsec1){ref-type="sec"}.Table 3Galactose-mimicking and other iminosugarsCompound(s)VirusSummary of ResultsBVDVDENVHCVJEVDGJ (Deoxygalactonojirimycin)XNo antiviral activity, CC~50~\>10,000 μMDGJ Derivative 6XMinimal to no antiviral activity, CC~50~\>250 μMMON-6d-DGJX**DENV-2** in MDMs: no inhibitory effect up to 100 μM.N7-DGJ (N7-oxanonyl-6deoxy-DGJ)XMDBK cells: IC~50~=2.5-125 μM depending on MOI (MOI 0.1 = 2.5 μM; MOI 1.0 = 125 μm), CC~50~\>4,000 μM\
No viral rebound after 22 passages in persistently infected MDBK cells when used in combination with IFN and RBVNB-DGJXXNo antiviral activity observed against **BVDV** in MDBK cells or **DENV-2** in MDMsNN-6deoxy-DGJXMDBK cells: IC~50~=2-25 μM, CC~50~=187.5 μMNN-DGJXXX**BVDV** in MDBK cells: IC~50~=12.5-25 μM, CC~5~0=237.5 μM **DENV-2** in MDMs, no antiviral activity (up to 31.6 μM)\
**HCV** in multiple genotypes and cell types: results varied, mostly ∼moderate inhibition of secreted infectious virus. No change in the electrophoretic mobility of E1 or E2 in Huh7 or S*f*9 cellsDMJ (1-Deoxymannojirimycin)XXXVirus secretion: **BVDV** in MDBK cells, minimal to no inhibition (up to 15000 μM); **DENV-**2 in PS cells, reduced by ∼6 log PFU/mL (at 200 μM/mL); **JEV** in PS cells, reduced by 0.6-1.0 log PFU/mL (at 200 μM/mL)[^3]

5.1. Flaviviruses {#sec5.1}
-----------------

The antiviral activity of iminosugars has been evaluated *in vitro* against multiple flaviviruses that pose a risk to human health, including all four DENV serotypes, with a strong focus on DENV-2 ([@bib109]), as well as JEV ([@bib175]), YFV ([@bib96]; [@bib168]), ZIKV ([@bib96]), WNV ([@bib25]; [@bib57]; [@bib168]), and the WNV variant strain, Kunjin virus (KUNV) ([@bib98]). A large number of iminosugars tested exhibited moderate to strong activity against flaviviruses *in vitro*, with IC~50~s ranging from 40 nM to 20 μM, although the level of inhibition was dependent on the molecule, cell type, and virus. The variable response of flaviviruses was demonstrated when the antiviral activity of celgosivir, the butylated pro-drug of the bicyclic iminosugar, CAST, was measured against all four DENV serotypes in multiple cell lines. Celgosivir inhibited DENV 1-4 in BHK-21 cells, with half maximal inhibitory concentrations (IC~50~s) in the nanomolar range ([@bib135]; [@bib164]). However, when efficacy was evaluated against DENV-1 and DENV-2 in Vero, Huh-7, and THP-1 cells, the IC~50~ varied, ranging from 0.75 -- 51 μM depending on the serotype, MOI, and cell type ([@bib164]).

The variable response of flaviviruses to iminosugar treatment was also recognized when the antiviral activity of CAST was evaluated against multiple viruses in parallel, including DENV, WNV, and YFV, in BHK-21 cells ([@bib168]). CAST treatment demonstrated inhibition against all four DENV serotypes, with \>95% reduction in the number of infected cells at 50 μM, as measured by immunostaining and flow cytometry, but resulted in minimal to no inhibitory effect against WNV at concentrations of up to 500 μM. Decreased inhibition of YFV was also observed compared to DENV, although there was still a 93% reduction at 500 μM relative to untreated cells. Plaque assays of supernatants confirmed this differential inhibitory response to treatment. Cells exposed to 50 μM of CAST had a 910-fold reduction in the production of infectious DENV particles, but only a 1.7- and 6.8-fold reduction was observed for WNV and YFV, respectively ([@bib168]). Despite the lack of antiviral activity of the bicyclic iminosugar CAST against WNV, several monocyclic iminosugars demonstrated strong anti-WNV activity in BHK-21 cells with dose-dependent inhibition and IC~50~s ranging between 1 -- 10 μM ([@bib25]; [@bib57]), although most were still less efficacious against WNV than DENV ([@bib25]).

The difference in sensitivity to iminosugar treatment between DENV and other flaviviruses was further demonstrated in HEK293 cells treated with IHVR-19029. The IC~50~ was 12.5 times higher for YFV than DENV, and 17.6 times higher for ZIKV than DENV ([@bib96]). Iminosugar efficacy has also been assessed against JEV in two published studies, both demonstrating a similar trend in antiviral activity when compared to DENV ([@bib175]). The DNJ derivative, *N*N-DNJ, which is known to have more potent antiviral activity than DNJ, inhibited the production of infectious JEV and DENV-2 in BHK-21 cells, however, the reduction was much greater at lower concentrations for DENV-2 compared to JEV. Other iminosugars (CAST, DNJ, and DMJ) had minimal to no impact on JEV replication, reducing viral RNA or infectious particle secretion by only ≤10-fold, but inhibited DENV secretion by up to 10^6^ plaque forming units (pfu). Similarly, *N*N-DNJ (100 μM) also reduced the secretion of infectious KUNV particles by more than 10^3^ pfu in Vero cells despite DNJ having no inhibitory effect when tested at the same concentration ([@bib98]). It is possible that differences in the number and/or location of glycosylation sites within viral proteins may contribute to the range in antiviral activity of iminosugars observed against different flaviviruses ([@bib109]).

Depending on the structure, iminosugars are capable of differentially inhibiting glycolipid or glycoprotein processing enzymes. The ability of some iminosugars to inhibit glycolipid processing was originally thought to contribute to the anti-DENV activity of this class of compounds ([@bib29]; [@bib141]; [@bib167]; [@bib171]). To better understand the mechanism iminosugars use to inhibit DENV, Sayce et al., evaluated the enzymatic targets of diverse bicyclic glucose- (CAST and celgosivir), monocyclic glucose- (DNJ, *N*B-DNJ, and *N*N-DNJ) and galactose-mimicking (deoxygalactonojirimycin (DGJ), *N*B-DGJ, and *N*N-DGJ) iminosugars, and correlated the target with the anti-DENV activity in primary human monocyte derived macrophages (MDMs) ([@bib141]). To identify the enzymatic target, they performed both *in vitro* glucosidase and glycosidase enzyme inhibition assays as well as measured the generation of glycosphingolipids (GSLs) or free oligosaccharides (FOS). Generation of triglucosylated or monoglucosylated FOS is used as a marker for ER α-glucosidase I and II inhibition, respectively, whereas the generation of the glycosphingolipid monosialodihexosylganglioside (GM3) is used as an indicator to measure glycolipid processing ([@bib2]; [@bib118]; [@bib127]; [@bib128]; [@bib162]). Sayce et al., demonstrated that monocyclic and bicyclic glucose-mimicking iminosugars inhibit glycoprotein processing, but only monocyclic compounds also inhibit glycolipid processing enzymes. Galactose-mimicking iminosugars inhibited glycolipid processing but not glycoprotein processing. Interestingly, the level of glucosyltransferase enzymatic inhibition correlated with the length of the alkyl tail, despite whether the iminosugar mimicked glucose or galactose, with longer tails having stronger inhibition ([@bib20]; [@bib21]; [@bib105]; [@bib106]; [@bib141]). Consistent with the enzymatic data, the glucose-mimicking iminosugars celgosivir and *N*B-DNJ, generated FOS ([@bib141]; [@bib162]). In contrast, DGJ derivatives reduced GM3 levels but did not generate triglucosylated or monoglucosylated FOS. Only the glucose-mimicking iminosugars that inhibited enzymes required for either glycoprotein processing, or both glycoprotein and glycolipid processing, were efficacious against DENV-2, whereas iminosugars with a galactose-like configuration had no measurable effect on the virus.

In a similar study, the glucose-mimicking iminosugar, UV-4B (M*O*N-DNJ), inhibited the enzymatic activity of both α-glucosidase I and II, but when an isomer of UV-4B designed to have a galactose-like configuration was tested, α-glucosidase I and II inhibition was lost ([@bib162]). MDMs treated with UV-4B containing either a glucose- or galactose-like configuration had reduced levels of GM3; however, only UV-4B with a glucose-like configuration generated FOS and was active against DENV, while the galactose-mimicking isomer lacking α -glucosidase inhibition was not efficacious against the virus.

Because iminosugars have the potential to alter the levels and/or folding of viral glycoproteins, treatment can ultimately result in decreased viral production or reduced infectivity of progeny viruses. *In vitro* studies have been performed to evaluate the effects of DNJ, *N*N-DNJ, CAST, and celgosivir on DENV or JEV glycoproteins, and to determine whether misfolded viral proteins are degraded or incorporated into newly released virus particles with decreased infectivity ([@bib33]; [@bib135]; [@bib141]; [@bib162]; [@bib175]). These studies demonstrated that treatment with iminosugars can alter glycan processing of the virus prM, E, and NS1 glycoproteins ([@bib33]; [@bib135]), prevent their interaction with calnexin ([@bib175]), reduce proper folding of prM and E ([@bib33]), inhibit the formation and stability of prM-E heterodimer complexes ([@bib33]), prevent the transport of E and NS1 from the ER to the Golgi ([@bib135]), and reduce secretion of both E and NS1 from cells ([@bib135]). The fact that iminosugars can block the transport and secretion of some flavivirus glycoproteins suggests that inhibiting ER α-glucosidase function likely results in decreased formation and secretion of new viruses rather than the formation of less infectious particles. Two separate studies have confirmed that this is the main mechanism employed by UV-4B, *N*B-DNJ, and celgosivir to inhibit DENV ([@bib141]; [@bib162]). In these studies, the authors performed plaque assays to measure the amount of infectious virus secreted from iminosugar treated MDMs and compared that to quantitative polymerase chain reaction results measuring the total amount of viral RNA secreted from the cells. Data from both studies were consistent and found that there was a direct correlation between the decrease in secreted infectious virus titer and total virus production, providing evidence that the viral glycoproteins are likely misfolded and targeted for degradation rather than partially misfolded and incorporated into newly released particles with decreased infectivity.

5.2. HCV and BVDV {#sec5.2}
-----------------

Prior to the development of *in vitro* culture systems for HCV, the closely related virus, bovine viral diarrhea virus (BVDV), was commonly used as a surrogate model. Cytopathic and noncytopathic BVDV culture systems have been used to evaluate the antiviral activity and mechanism of action of iminosugars in Madin-Darby bovine kidney (MDBK) cells ([@bib14]; [@bib26]; [@bib28]; [@bib39]; [@bib40]; [@bib57]; [@bib66]; [@bib69]; [@bib73]; [@bib103]; [@bib121]; [@bib169]; [@bib173]; [@bib181]; [@bib189]). Several DNJ derivatives were shown to inhibit BVDV by preventing the secretion of viral particles and viral RNA ([@bib39]; [@bib73]; [@bib189]). Similar to subsequent observations for flaviviruses, the antiviral effect elicited by the long-alkyl-chain DNJ derivative, *N*N-DNJ, was stronger than that of the short-alkyl-chain derivative, *N*B-DNJ. Treatment with DNJ derivatives was also shown to result in the assembly and release of low levels of viral particles with decreased infectivity ([@bib39]). The production of noninfectious particles was less pronounced when cells were treated with *N*B-DNJ compared to *N*N-DNJ, which may account for the stronger anti-BVDV activity associated with the long-alkyl-chain derivatives ([@bib39]).

To further evaluate the impact of the alkyl-chain length, as well as other potential inhibitory mechanisms of iminosugars, Durantel, et al., evaluated and compared the anti-BVDV activity of long and short alkyl-chain glucose-derived DNJ derivatives to that of long-alkyl-chain galactose-derived iminosugar derivatives of DGJ, which do not inhibit ER α-glucosidases ([@bib39]). Both DGJ and DNJ derivatives inhibited BDBV in cell culture, unlike what was later observed for flaviviruses, in which only DNJ derivatives demonstrated antiviral activity. However, only the long-alkyl chain DGJ derivative and not the short-alkyl chain derivative was efficacious against BVDV. This effect was solely the consequence of the production of noninfectious virions, rather than a reduction in viral secretion. Deletion of the viral membrane-spanning protein p7 has a similar impact on BVDV replication *in vitro*, also resulting in the production of viral particles with decreased infectivity without inhibiting viral secretion in media ([@bib62]). P7 was also shown to be essential for the production of infectious HCV virus ([@bib72]; [@bib139]; [@bib151]). The long-alkyl-chain iminosugar derivatives, *N*N-DNJ, *N*7-DGJ, and *N*N-DGJ, were found to inhibit HCV p7 ion channel activity in a dose-dependent manner ([@bib123]). Interestingly, DENV-2 and JEV, which do not encode for the p7/p13 protein, are not inhibited by DGJ derivatives ([@bib175]).

While many of the initial studies used BVDV as a surrogate for HCV, the use of HCV virus like particles (VLPs) and the later developed *in vitro* HCV infectivity systems helped to confirm the anti-HCV activity of iminosugars against multiple genotypes ([Figure 1](#fig1){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). Exposure to *N*N-DNJ inhibited the release of HCV particles in a dose-dependent manner in Huh7 cells transfected with JFH-1 or chimeric derivatives containing structural proteins of other genotypes, including 1a (H77), 1b (CON-1), 2a (JS, CJ-1), and 3a (452), but was less active against the 3a (452) chimera ([@bib56]). To evaluate the potential cause for decreased activity against the 3a (452) chimera, the impact of iminosugar treatment on p7 function was evaluated by measuring the ability of p7 to release a fluorescent dye from liposomes. *N*N-DNJ had minimal to no impact on 3a (452) p7 function; however, *N*N-DNJ reduced the activity of p7 from all other HCV isolates tested, correlating with the *in vitro* viral inhibition data ([@bib56]). Alignment of the p7 sequences from different HCV isolates identified a polymorphism (F25A) in the 3a HCV genotype ([@bib50]). When a mutant chimeric JFH-1 virus containing the p7 F25A polymorphism was exposed to *N*N-DNJ or *N*N-DGJ treatment, minimal to no effect was observed on virus secretion, whereas secretion of wild-type JFH-1 virus was largely inhibited following exposure to the iminosugars.

Data from mechanistic studies show that iminosugars have similar effects on HCV and the surrogate BVDV culture systems. Iminosugars prevent the release of BVDV and HCV viral RNA and infectious virus with minimal to no impact on viral RNA synthesis ([@bib39]; [@bib73]; [@bib133]; [@bib189]). Treatment with iminosugars also alters the interaction between BVDV or HCV glycoproteins and ER chaperone proteins ([@bib14]; [@bib27]; [@bib31]; [@bib38]), and results in an electrophoretic mobility shift caused by deficient glycan processing, which is accompanied by the production of misfolded glycoproteins and/or decreased formation of E1-E2 heterodimers ([@bib14]; [@bib27]; [@bib133]).

The antiviral effect of *N*B-DNJ was attributed to inefficient glucose trimming of BVDV envelope glycoproteins by the ER α-glucosidases, inhibiting the association of the envelope proteins with calnexin and resulting in the production of misfolded viral envelope glycoproteins and decreased E1-E2 heterodimer formation ([@bib14]). The HCV glycoproteins E1 and the E2 precursor, E2-NS2, were found to interact with multiple ER chaperones, although only calnexin interacted primarily with monomers or noncovalent E1-E2 complexes, which are formed prior to the final folding stage ([@bib31]). By using HCV virus-like particles (VLP), it was shown that iminosugars inhibit N-linked glycan processing to interrupt this interaction, resulting in the production of VLPs containing unprocessed N-linked glycans and misfolded proteins that have a decreased binding affinity to hepatoma cells ([@bib27]).

In addition to having a direct effect on viral glycoproteins, it is possible iminosugars may also regulate infectivity by altering the expression or perturbing the function of host glycoproteins that are required for viral entry and replication. Although changes to host glycoproteins have been implicated as a contributor to the antiviral activity of iminosugars against the severe acute respiratory syndrome coronavirus (SARS-CoV), the impact of potential alterations to host-protein glycosylation on *Flaviviridae* entry or replication has not been evaluated ([@bib188]). Miller et al., recently reported that iminosugars may alter the function and expression of some host glycoproteins involved in DENV replication, although the possible effect these changes may have on DENV infection is not yet understood ([@bib107]).

*6*. *In vivo* efficacy of iminosugars against *Flaviviridae* {#sec6}
=============================================================

Despite the extensive *in vitro* efficacy studies that have been performed evaluating the antiviral activity of iminosugars against multiple members of the *Flaviviridae* family, *in vivo* studies have been primarily limited to murine models of DENV infection, particularly DENV-2 (for a more in-depth review, refer to [@bib109]). This has been due, in part, to a lack of suitable small animal models available for HCV and BVDV ([@bib10]), and because of the stronger *in vitro* antiviral activity observed against DENV compared to other flaviviruses. Animal models of JEV and WNV disease are the only *Flaviviridae* infection models, other than DENV, that have been used in published studies to evaluate the antiviral activity of iminosugars ([@bib168]; [@bib175]). In fact, the first *in vivo* model system used to evaluate the efficacy of an iminosugar against a *Flaviviridae* family member was the murine model of JEV disease ([@bib175]). A survival benefit was observed in comparison to control treated animals when female ICR mice were administered *N*N-DNJ (200 mg/kg, oral administration, once daily) beginning one day before simultaneous intraperitoneal and intracranial challenge with JEV. Considering that *N*N-DNJ was notably more efficacious against DENV-2 than JEV (RP9 strain) *in vitro*, the observation that *N*N-DNJ protected mice against a lethal JEV infection *in vivo* supported the continued examination of iminosugars against other flaviviruses.

The potential *in vivo* anti-flavivirus activity of iminosugars was next examined against WNV and DENV-2 ([@bib168]). C57BL/6 mice were infected with 10^2^ pfu of WNV (3000.0259 strain) by footpad injection and A/J mice were infected intracranially with 10^5^ pfu of mouse-neuroadapted DENV-2 (NGC strain). Mice were treated intraperitoneally with up to 250 mg/kg CAST or vehicle once daily beginning on the day of infection ([@bib168]). While CAST treatment resulted in a significant survival benefit against DENV-2 compared to control treated mice, it had no measurable effect on mortality when mice were infected with WNV. This *in vivo* response correlated with observations *in vitro*, where CAST had minimal to no inhibitory effect against WNV at concentrations of up to 500 μM. However, unlike CAST, which is a bicyclic iminosugar, several monocyclic iminosugars, such as *N*B-DNJ ([Table 1](#tbl1){ref-type="table"}), have proven to be efficacious *in vitro* against WNV but have not been tested *in vivo* ([@bib25]; [@bib57]). Despite the lack of activity of CAST against WNV in the murine model, it is possible treatment with monocyclic iminosugars would result in a survival benefit based on the results of *in vitro* studies. These monocyclic compounds may elicit their anti-WNV activity through a separate or additional mechanism, such as through their ability to also inhibit the glycolipid biosynthesis pathway, although alteration of glycosphingolipid activity was shown to not be the mechanism of anti-DENV activity for the iminosugar, UV-4 ([@bib141]; [@bib162]).

Two iminosugars, UV-4B and celgosivir, successfully protected mice against a lethal challenge with DENV-2 when treatment was delayed and initiated up to 48 hours post-challenge. ([@bib124]; [@bib135]; [@bib162]). Both of these molecules have advanced to clinical trials, with UV-4B being evaluated in early phase safety and pharmacokinetic studies, and celgosivir in adults with confirmed dengue fever (discussed below) ([@bib94]; Spurgers et al., unpublished data). Several other iminosugars have demonstrated efficacy in murine models of DENV-2 disease, including antibody dependent enhancement (ADE) models. ADE is an increase in the infectivity of a virus due to preexisting, poorly neutralizing antibodies that can facilitate entry of the virus into host cells and exacerbate disease severity. The highest known risk of severe dengue disease is in patients previously infected with a different DENV serotype who have intermediate levels of pre-existing anti-DENV antibodies ([@bib75]). Murine models of ADE have been used to better represent severe DENV infections in humans. Passive administration of anti-DENV antibodies has been shown to be sufficient to enhance DENV disease in mice using both mouse-adapted and clinical DENV isolates ([@bib6]). Clinical features of lethal DENV-ADE disease models include thrombocytopenia, vascular leakage, elevated serum cytokine levels, and increased systemic viral burden in serum and tissue phagocytes, all hallmarks of severe dengue disease in humans ([@bib6]).

Celgosivir is the only iminosugar for which data has been published evaluating the *in vivo* efficacy against a DENV serotype other than DENV-2 ([@bib164]). AG129 mice were infected intravenously with 7 x 10^7^ pfu DENV-1 (2402 strain) after being exposed to the 4G2 anti-E antibody to induce ADE, and mice were treated orally with vehicle or celgosivir (10 mg/kg or 50 mg/kg) twice daily, starting at the time of infection. Although a survival benefit was not observed for animals in the low-dose group (10 mg/kg), all mice in the high-dose group (50 mg/kg) survived infection.

7. Anti-*Flaviviridae* activity of iminosugar drug combinations {#sec7}
===============================================================

Drug combination therapies are often considered for the treatment of viral infections. Combination treatment may minimize the potential for resistant strains to develop against an individual drug, as well as maximize compound efficacy if a synergistic benefit is observed with the combination treatment. Iminosugars were first evaluated in clinical trials for an antiviral indication as part of a combination therapy with zidovudine (AZT) for the treatment of HIV infections, although these studies did not proceed further than Phase II ([@bib47]). Prior to the recent development and approval of highly efficacious direct-acting antivirals against HCV (discussed in more detail below), the standard therapy for patients consisted of a less effective combination of interferon (IFN) and ribavirin, which could be associated with multiple, and sometimes serious, side effects ([@bib35]; [@bib41]; [@bib43]; [@bib99]). In pursuit of improving the treatment regimen, the potential benefit of incorporating iminosugars into this therapeutic modality was evaluated. *In vitro* drug synergy studies were performed using BVDV culture systems to evaluate the antiviral efficacy of iminosugars when used in combination with IFN, ribavirin, or a second iminosugar ([@bib69]; [@bib121]; [@bib169]; [@bib173]). When BVDV-infected MDBK cells were treated with a combination of two iminosugars, CAST and *N*B-DNJ, the observed antiviral activity was additive with no statistically significant synergistic or antagonistic antiviral effect, which would be expected considering CAST and *N*B-DNJ have the same cellular target ([@bib121]). However, when *N*B-DNJ was combined with IFN-α2b under the same conditions, treatment resulted in synergistic antiviral activity against BVDV. In a separate study, synergistic antiviral activity was also observed when BVDV-infected MDBK cells were treated with celgosivir plus INF-α or celgosivir plus ribavirin in two or three out of four experiments, respectively ([@bib169]).

To extend observations beyond dual-drug treatment combinations, the antiviral activity of triple-drug combinations, consisting of IFN, ribavirin, and an iminosugar, was evaluated in MDBK cells persistently infected with a noncytopathic strain of BVDV ([@bib173]). Cells were passaged in the presence of IFN and ribavirin, with or without the addition of one of three iminosugars (*N*7-DGJ, *N*B-DNJ, or *N*N-DNJ). Treatment was sustained over several passages and the impact on long-term viral clearance was measured following removal of one or all drugs. Cells treated with the dual-drug combination of IFN and ribavirin maintained viral clearance only if treatment was continued; removal of the drugs resulted in a loss of viral clearance over time. However, with the addition of an iminosugar to the treatment regimen, viral clearance was sustained, even after removal of the drugs. *N*B-DNJ had the greatest impact on maintaining viral clearance. Treatment of cells for nine weeks with the three-drug cocktail containing 10 μM *N*B-DNJ was sufficient to permanently eliminate the virus.

The antiviral activity of iminosugar drug combinations was also evaluated against members of the *Flavivirus* genera. Synergistic antiviral activity was observed when HEK293 cells were infected with the vaccine strain of YFV (17D) and treated with the iminosugar, IHVR-19029, and the viral RNA polymerase inhibitor, favipiravir (T-705). While the antiviral efficacy of this drug combination was not evaluated in an *in vivo* flavivirus disease model, T-705 was found to potentiate the antiviral activity of IHVR-19029 in a murine model of Ebola virus disease ([@bib96]). Ribavirin was also found to have a synergistic antiviral effect *in vitro* against DENV-2 when combined with the iminosugar CM-10-18 ([@bib24]). In this study, the enhanced activity of ribavirin by CM-10-18 was confirmed using a murine model of DENV-2 infection. These studies support the potential use of iminosugars in drug combination therapies for the treatment of flavivirus infections.

8. Broad-spectrum antiviral activity of iminosugars {#sec8}
===================================================

Considering that many viruses exploit the host's N-linked glycosylation machinery for the morphogenesis of progeny virus particles, it is not surprising that the antiviral activity of some iminosugars expands far beyond members of the *Flaviviridae* family. Several iminosugars have proven to be efficacious in small animal models of disease for influenza A, influenza B, herpes simplex, Ebola, and Marburg viruses ([@bib17]; [@bib26]; [@bib150]; [@bib160]; [@bib161]; [@bib184]), as well as against many diverse DNA and RNA viruses using cell culture systems (refer to table 20.3 from [@bib109] and [table 2](#tbl2){ref-type="table"} from [@bib23], [@bib26]). Included in this group of viruses are the coronaviruses, SARS-CoV and the recently identified, SARS-CoV-2, responsible for the ongoing global pandemic ([@bib174]; [@bib188]; [@bib134]). Iminosugars have been shown to decrease the production of infectious virions *in vitro* as well as alter the N-linked glycan structure of the SARS-CoV and SARS-CoV-2 cellular receptor, angiotensin I-converting enzyme 2 (ACE2), impairing entry of SARS-CoV and human coronavirus NL63 (HCoV-NL63) spike glycoprotein-pseudotyped lentiviral particles through a post-receptor binding mechanism ([@bib188]).

Similar to what has been observed for *Flaviviridae*, the antiviral activity of iminosugars against other viruses varies with the compound, virus, and cell type. The mechanism of antiviral activity can also vary depending on the compound and the virus. Influenza virus and HIV are both good examples of the differential effects that can be observed following treatment with iminosugars. Extensive research has been performed evaluating the effect of iminosugars against influenza virus, which is discussed further in a separate review ([@bib129]). Interestingly, iminosugars tend to have low potency against influenza virus *in vitro*, yet treatment provides partial or full protection against lethal infections in murine models of disease ([@bib161]). Studies evaluating the mechanism of anti-HIV activity of iminosugars found that treating infected cells with iminosugars can alter the glycosylation of the viral gp120 glycoprotein ([@bib45]; [@bib46]). This can impair the ability of new HIV particles to enter cells following binding to CD4 rather than reduce the production of secreted progeny viruses, as is observed for flaviviruses. Despite the differences in the level and mechanism of antiviral activity of iminosugars, the broad antiviral potential of this class of compounds supports further research into the potential use of these molecules for the treatment of diverse viral infections.

9. High barrier to development of *in vivo* drug resistance to iminosugars {#sec9}
==========================================================================

One of the many challenges in the antiviral drug development field is understanding how to design compounds that will remain efficacious despite the high genetic variability of most viruses, which leads to rapid generation of antiviral drug resistance. For example, influenza virus resistance to oseltamivir (Tamiflu®) has been noted after a single mutation, and recent publications discussed resistance to baloxavir marboxil (XOFLUXA^TM^), which was approved in the U.S. in October, 2018 ([@bib12]; [@bib63]; [@bib104]; [@bib119]; [@bib153]; [@bib154]). Current strategies proposed for overcoming this challenge include the development of drug combination therapies that contain drugs targeting multiple viral proteins and HTAVs, both of which are less likely to generate resistant strains compared to direct-acting antivirals targeting a single viral protein. For HTAVs, this is due to the detrimental effect resistant mutations would likely have on viral replication if the virus was critically dependent on the host factor targeted by the drug.

In order to determine whether DENV has the potential to mutate and develop resistance to iminosugars, Plummer et al., performed an *in vivo* passaging study in mice ([@bib129]). DENV (DENV-2 strain S221) was passaged in STAT1^-/-^/2^-/-^ mice treated orally with either UV-4B or vehicle (water) for 4 serial passages; samples were pooled by group after each passage and evaluated to determine whether the virus could mutate and develop resistant strains. Only 13 nonsynonymous mutations were identified in pooled samples from UV-4B treated mice, 12 of which were also identified in virus isolated from vehicle-treated control animals. Viruses isolated after each passage were still susceptible to treatment with UV-4B. Considering that DENV is transmitted from invertebrate (mosquito) to vertebrate hosts rather than from vertebrate to vertebrate (e.g., mouse to mouse), and to address the possible impact pooling the samples may have had on diluting mouse-specific responses, the authors also identified mutations in viruses isolated from individual mice after a single passage in the presence or absence of UV-4B. After only a single passage *in vivo*, 19 nonsynonymous mutations were identified in DENV glycosylated proteins (M, E, and NS1) that were specific to UV-4B treatment. Despite the increased number of nonsynonymous mutations identified, these viruses were still susceptible to treatment with UV-4B providing no evidence that viral escape mutants were generated after single or multiple cycles of proliferation in the presence of the iminosugar in vivo. A high barrier to the development of drug resistant DENV viral strains was also observed *in vitro* when DENV was passaged up to 30 times in cells in the presence of UV-4B (Warfield et al., unpublished data).

The potential for UV-4B to induce the development of drug resistant viral strains was also evaluated in a murine model of influenza A virus ([@bib163]). Similar to what was observed in the DENV model, when mouse-adapted influenza A virus was passaged in the presence or absence of UV-4B for five successive passages, the virus maintained sensitivity to UV-4B treatment in mice. Mice infected with recombinant viruses containing individual or combinations of nonsynonymous mutations identified in the passaged virus were also still sensitive to UV-4B treatment, further confirming the high genetic barrier to the generation of drug resistant strains following exposure to an iminosugar antiviral.

10. Clinical Trials: Iminosugars as antivirals {#sec10}
==============================================

Three candidate iminosugars have advanced to clinical trials to evaluate safety and efficacy against viral infections: celgosivir (HCV, DENV, and HIV), *N*B-DNJ (HIV), and UV-4B (DENV). HCV was the first of the two *Flaviviridae* family members to be included in a clinical trial assessing the therapeutic potential of an iminosugar ([Table 4](#tbl4){ref-type="table"} ). Prior to the approval of current direct-acting antiviral therapies for HCV infections, several Phase 2 clinical trials were completed to evaluate the safety and efficacy of celgosivir against chronic HCV genotype 1 infections when administered as a monotherapy (NCT00157534) or in combination with PEGylated IFNα2b or PEGylated IFNα2b plus ribavirin (NCT00332176 and NCT00217139). In the initial Phase 2a randomized, dose-ranging trial, 43 patients with chronic HCV infections who were either IFN-intolerant or had never been treated with IFN were enrolled to receive celgosivir treatment (200 or 400 mg once daily or 200 mg twice daily) for 12 weeks. Viral load reduction was only observed for 2 of the 35 patients who completed the full treatment course ([@bib37]; [@bib42]). Although well tolerated, celgosivir treatment only provided a measurable therapeutic benefit when used as part of a drug combination in other trials. Clinical trials were conducted to evaluate the safety and efficacy of celgosivir plus either PEGylated IFNα2b or PEGylated IFNα2b and ribavirin in patients not previously treated with IFN (NCT00332176) or patients who did not respond or only partially responded to prior treatment with PEGylated IFNα2b (NCT00217139). Non-responders treated with the triple drug combination had an increased average early viral response (42%) when compared to patients that received the standard treatment of PEGylated IFNα2b and ribavirin (10%), and a greater reduction in viral load (-1.63~10~) compared to the control group receiving the standard treatment (-0.92 log~10~) (NCT00217139) ([@bib37]). A follow up trial was conducted (NCT00292084) as an extension of the original clinical trial (NCT00217139 to allow patients from the original trial an opportunity to switch treatments and receive therapy for an additional 36 weeks, although results from this study are not yet reported.Table 4Clinical stage development of iminosugars for the treatment of *Flaviviridae* infections.Table 4CompoundIndication/VirusStudy DetailsStudy Endpoint/ReadoutsResultsReferencesCelgosivirHCV (genotype 1)Phase 2a randomized, dose-ranging trial; 43 adult participants, ages 18-65 with chronic HCV infections who were IFN-intolerant or never treated with IFN; 200 or 400 mg once daily or 200 mg twice daily for 12 weeksSafety and efficacy (viral load reduction)Viral load reduction observed for 2 of the 35 patients who completed the full treatment course. Well tolerated but no measurable therapeutic benefit.NCT00157534;\
[@bib37];\
[@bib42]DENVPhase 1 randomized, double-blind, placebo-controlled study; 50 adult participants, ages 21-60 with uncomplicated DENV fever (fever ≥38°C for less than 48 h); 24 participants received celgosivir (400 mg loading dose, 200 mg maintenance dose every 12 h for a total of 9 doses) and 26 participants received placebo controlSafety, pharmacokinetics, and efficacy (primary: viral load reduction and fever reduction; secondary: NS1 and NS1 clearance)Celgosivir was well tolerated by patients; no measurable reduction in viral load or fever burden.NCT01619969;\
\
[@bib94]Phase 2 double-blind, placebo-controlled study; Adult participants ages 21-65 with acute febrile illness with fever \>37.5°C for less than 48 h); celgosivir arm: 150 mg every 6 h for a total of 20 dosesSafety and efficacy (primary: viral load reduction, AUC; secondary: fever clearance time, duration of illness, time to NSI clearance)NA/not yet recruitingNCT02569827Celgosivir +/- standard care (PEGylated IFNα2b + Ribavirin)HCV (genotype 1)Phase 2 randomized, active controlled study; 50 adult participants, ages 18-65 with chronic HCV infections who were not previously treated with IFN; 400 mg or 600 mg celgosivir qd plus standard care, or standard care alone, for 12 weeksSafety, tolerability, pharmacokinetics, efficacy (viral load reduction)NANCT00332176Celgosivir + PEGylated IFNα2b\
+/- RibavirinHCV (genotype 1)Phase 2 randomized, active controlled study; 60 participants ages 18-65 with chronic HCV infections who did not respond or only partially responded to prior treatment with PEGylated IFNα2b; Study arms not indicated, 12-week treatmentSafety and efficacy (viral load reduction)Non-responders treated with the triple drug combination had an increased average early viral response (42%) when compared to patients that received the standard treatment of PEGylated IFNα2b and ribavirin (10%), and a greater reduction in viral load (-1.6310) compared to the control group receiving the standard treatment (-0.92 log10).NCT00217139HCV (genotype 1)Phase 2 (extension of clinical trial NCT00217139); allow patients to switch and/or continue celgosivir (plus IFN or IFN and ribavirin) treatment for an additional 36 weeksSafety and efficacy (viral load reduction)N/ANCT00292084UV-4BDENVPhase 1 randomized, double-blind, placebo-controlled, single-ascending dose study; 64 participants, healthy subjects received placebo control or up to 1,000 mg UV-4B (single dose)Safety, tolerability, and pharmacokineticsNo serious adverse events.NCT02061358; Spurgers et al., unpublished dataPhase 1 randomized, double-blind, placebo-controlled, multiple ascending dose study; healthy adult subjects, ages 18-45; placebo or UV-4B TID treatment (ascending doses) for 7 daysSafety, tolerability, and pharmacokineticsTerminated early before DENV-infected patients were dosed; product development ceased for business reasons.NCT02696291[^4]

More recently, celgosivir entered a proof of concept, Phase 1b double-blind, randomized clinical trial (NCT01619969) for the treatment of DENV infections in adult patients with uncomplicated dengue fever (as defined by patients having a fever of at least 38°C for less than 48 h) ([@bib94]). Fifty patients were enrolled in the study, with 24 assigned to the celgosivir group and 26 to the placebo group. Patients receiving celgosivir treatment were administered an initial loading dose of 400 mg, followed by a maintenance dose of 200 mg every 12 h. Treatment was continued until patients received a total of nine doses. While celgosivir was well tolerated by patients in the test group, there was no measurable reduction in viral load or fever burden. It is possible that use of a subtherapeutic dose may have contributed to these results. A follow-up Phase 2 clinical trial (NCT02569827) was recently approved to evaluate a higher-dose regimen of 150 mg, administered every 6 hours for a total of 20 doses, but is not yet recruiting. A potent derivative of *N*B-DNJ, UV-4B, also advanced to Phase 1 clinical trials as a prelude to trials in DENV infections. No serious adverse events were reported in a Phase 1 single-ascending dose study at doses up to 1,000 mg (NCT02569827). However, the subsequent Phase 1 multiple-ascending dose trial (NCT02696291) was terminated early before DENV-infected patients were dosed.

The iminosugars *N*B-DNJ and celgosivir also entered clinical trials as a combination therapy with zidovudine for HIV infections (celgosivir: NCT00002151, NCT00002150; NB-DNJ: NCT00001993, NCT00002079, NCT00000791), but neither advanced past Phase 2 ([@bib47]). These studies demonstrated that both *N*B-DNJ and celgosivir are well tolerated by patients, although minor but reversible osmotic diarrhea was observed due to inhibition of α-glucosidases in the gut.

11. Other *Flaviviridae* ER-associated host dependency factors {#sec11}
==============================================================

Several gain- or loss-of-function genetic screens have been performed to identify host factors required for flavivirus or HCV replication in various cell lines ([@bib87]; [@bib95]; [@bib100]; [@bib125]; [@bib140]; [@bib185]). While considerable overlap was observed for flavivirus host dependency factors between screens, there was substantial diversity between genes required for DENV and HCV replication, with DENV being largely affected by the loss of protein expressing genes that comprise different ER-associated protein complexes, while viral receptors metabolic enzymes and RNA binding proteins were among the genes that had the most significant impact on HCV replication.

Several screens identified members of the OST complex, which is an essential component in the N-linked glycosylation pathway, as being essential for flavivirus propagation. The catalytic subunit of the OST complex consists of one of two paralogous forms of STT3, STT3A and STT3B, which have partial functional redundancy ([@bib144]). STT3A/B associates with at least six other subunits, including Ribophorin I (RPN1), ribophorin II (RPN2), DDOST (OST48), DAD1, OST4, and MAGT1 (IAP) or Tusc3 (N33), to make up different forms of the complex ([@bib144]). Viral dependency on OST was confirmed for multiple flaviviruses, including DENV 1-4, WNV, ZIKV, JEV and YFV, although dependency varied between virus, cell-type, and subunit ([@bib87]; [@bib100]; [@bib140]; [@bib185]). STT3A and STT3B expression were shown to be required for DENV propagation, while STT3A, but not STT3B, is required for ZIKV, JEV, WNV, and YFV replication in 293T and/or HAP1 cells. Despite the involvement of the OST complex in the N-linked glycosylation pathway, the N-glycosylation catalytic activity of STT3A/B was not required for DENV replication ([@bib87]; [@bib100]). Expression of a STT3A or STT3B mutant lacking catalytic activity was able to overcome DENV inhibition observed in STT3A or STT3B knockout cell lines, respectively, suggesting the mechanism is at least partially independent of viral protein glycosylation Instead, the OST complex was found to interact with viral NS proteins of the RNA replication complex, demonstrating that OST plays a structural role though a physical interaction with a viral protein that is required for DENV RNA replication. Although, because STT3A and STT3B may have partially redundant functions, a possible impact on N-glycosylation of viral glycoproteins cannot be eliminated as any substantial change on viral protein glycosylation would be observed at a later stage in the viral replication cycle than the primary mechanism observed.

The anti-flavivirus potential of perturbing OST function was confirmed using the OST inhibitor, NG-1, which was shown to have broad anti-flavivirus activity *in vitro*, reducing viral RNA production of DENV, ZIKV, WNV and YFV ([@bib90]; [@bib131]). The mechanism of anti-flavivirus activity of NG-1 was also shown to be independent of the catalytic N-glycosylation function of the OST complex; however, it is possible that higher concentrations could alter viral protein glycosylation ([@bib131]).

In addition to the OST complex, these genome-wide screens identified multiple other host protein candidates important for flavivirus replication that could be targeted in the future development of novel HTAVs. Specifically, several other ER-associated proteins were identified in loss-of-function screens as flavivirus host dependency factors, including members of the translocon-associated protein (TRAP) complex, ERAD pathway, ER-associated signal peptidase complex (SPCS1), and the ER membrane complex (EMC) ([@bib83]; [@bib100]; [@bib140]; [@bib185]). The TRAP complex, along with Sec61 and OST complexes, form the translocon where the cotranslational insertion of proteins occurs in the ER, and is required for proper expression of ER-targeted glycoproteins ([@bib15]; [@bib126]). The SPCS complex cleaves signal peptides on various membrane-associated and secreted proteins. SPC1 was demonstrated to affect posttranslational processing of the JEV NS2B protein rather than viral entry, RNA replication, or translation ([@bib97]). The EMC complex may associate with the OST complex and is involved in the processing and maturation of transmembrane proteins ([@bib158]; [@bib183]). EMC proteins were found to have a role in regulating the levels of host AXL or heparin sulfate protein expression on the cell surface, which is important for the early phase of replication for DENV and ZIKV ([@bib70]; [@bib102]; [@bib136]; [@bib140]). Infectivity assays using Huh-7 cells lacking expression of the EMC component, EMC4, confirmed the requirement of this host protein for DENV-2, DENV-4, YFV, and ZIKV replication, although WNV replication was unchanged in EMC4 knockout cells ([@bib7]). Similarly, the EMC2 subunit was also found to be dispensable for WNV propagation, although replication appeared to be slightly delayed ([@bib95]).

12. Other clinical therapeutics for the treatment of flavivirus infections {#sec12}
==========================================================================

While numerous vaccines and other biologics have advanced to clinical development for the prevention or treatment of flavivirus infections, only a few small molecules have reached this stage of development, with most targeting DENV ([Table 5](#tbl5){ref-type="table"} ). As of August 2019, all drugs that have been evaluated in the clinic for DENV (safety and/or efficacy studies) were previously approved for other indications, except for three experimental drugs: the iminosugars UV-4B and celgosivir (discussed above), and balapiravir. Balapiravir is a prodrug of a cytidine analog that functions by inhibiting the viral polymerase protein and was originally developed for the treatment of chronic HCV infections. Balapiravir demonstrated promising results against HCV in a Phase 1b study ([@bib137]); however, clinical development was terminated following dose-related adverse events in patients in a Phase 2 clinical trial (NCT00517439) investigating extended combination therapy with pegylated IFN and ribavirin ([@bib116]; [@bib137]). The positive safety profile observed during the short course treatment in the Phase 1b trial led to balapiravir being investigated for the treatment of DENV infections, which would require only acute treatment unlike chronic HCV infections ([@bib137]). Although well-tolerated, balapiravir did not measurably reduce viremia, NS1 antigenemia, or fever clearance time. Failure to meet the efficacy endpoint is thought to be due, in part, to a decrease in the conversion of the prodrug to the active triphosphate form in infected patients ([@bib30]).Table 5Clinical stage development of small molecules for the treatment of flavivirus infections or symptoms associated with disease caused by flavivirus infections.Table 5CompoundIndication/VirusStudy DetailsStudy Endpoint/ReadoutsResultsReferences**Approved Drugs**ChloroquineDENVRandomized, double-blind, placebo-controlled study; Participants included patients over 14 years of age hospitalized in Ho Chi Minh City, Vietnam, with suspected uncomplicated DENV infections, including 257 confirmed cases; Participants received 600 mg chloroquine (day 1-2) and 200 mg on day 3, or placebo controlSafety and efficacy (negative RT-PCR detection of viral RNA in plasma and clearance of NS1 from blood).Trend of lower incidence of hemorrhagic fever with chloroquine treatment; no reduction in duration of NS1 antigenaemia or DENV viremia; treatment was associated with more adverse events (e.g. vomiting) compared to the placebo-treated control group, with one case of hematemesis, with no reduction in the duration of NS1 antigenaemia or DENV viremia.ISRCTN38002730;\
[@bib156]IvermectinDENVPhase 2/3, randomized, double-blind, placebo-controlled study; 360 participants, children and adult patients ages 15 and older with DENV infection (fever \>38°C for ≤ 72 h); 200-400 μg/kg ivermectin or placebo once daily for 2 or 3 daysSafety and efficacy (primary: time to resolution of viremia; secondary: time to clearance of NS1 antigen, time until fever resolved)Preliminary data suggests that there is no difference in viremia with ivermectin treatment. Treatment may result in a reduction in body temperature and NS1 serum levels with administration of a high dose.NCT02045069;\
[@bib93]DENVPhase 2 non-randomized, open label study; Pediatric participants, ages 1-15, with DENV infections (acute fever within last 72 h); 400 μg or 600 μg ivermectin per 1 kg body weight once daily for three daysPrimary: pharmacokinetics, Secondary: pharmacodynamics, safety (occurrences of adverse events), viremia and NS1 antigenemia clearanceNA; recruiting, current status unknownNCT03432442KetotifenVascular leakage during DENV feverPhase 4 randomized, double-blind, placebo-controlled study; Adult participants ages 21-60 with DENV fever (≥37.5°C for ≤ 72 h), excluding patients with severe dengue; 2 mg Ketotifen or placebo BID for a total of 10 dosesEfficacy (primary: fluid accumulation in the pleural cavity; secondary: multiple secondary outcome measures)NA; recruitment status unknownNCT02673840LovastatinDENVPhase 2, randomized, double-blind, placebo-controlled study; Adult Vietnamese participants with acute DENV infections; 40 mg or 80 mg lovastatin or placebo control once daily for up to 5 daysSafety and tolerability of lovastatin, including rate of adverse eventsWell-tolerated; No benefit observed, although not powered to statistically measure efficacy and selected dose may have been subtherapeutic.ISRCTN03147572;\
[@bib170]OseltamivirThrombocyt-openia and plasma leakage in DENV infectionsPhase 2 randomized, placebo-controlled, double-blinded study; Participants ages 16 and above with DENV infections (fever ≤ 6 days, admitted to hospital); 75 mg oseltamivir phosphate BID or placebo for a maximum of 5 daysSafety and effects of treatment on plasma leakage and thrombocytopenia (time to platelet recovery)NA; ongoing, no longer recruitingISRCTN35227717PrednisolonePrevention of DENV associated complications without prolonging viral clearanceRandomized, placebo-controlled, partially blinded study; Participants included Vietnamese children and young adults, ages 6-20, with suspected DENV infection (fever ≤72 h); Low or high dose prednisolone (doses based on body weight ranges) or placebo daily for 3 daysSafety (clinical and virological parameters)Adverse effects, including prolongation of viremia, were not observed in patients following prednisolone treatment. No benefit to disease progression observed with prednisolone treatment compared to the placebo treated control group, although the study was not powered to statistically assess such effects.ISRCTN39575233;\
[@bib155]**Novel Inhibitors**AVI-4020WNV neuroinvasive diseasePhase 1 exploratory study; Adult participants ages 18 to 75 with presumptive acute neuroinvasive WNV diseaseSafety, tolerability, pharmacokinetics, and potential effectiveness on neurological status (measured by NIH Stroke Scale and Galsgow Coma Score)Study terminated due to limited number of patients meeting eligibility criteria.NCT00091845BalapiravirDENVPhase 1, randomized, double-blind, placebo-controlled study; 64 adult male participants, ages 18 -- 65, with confirmed DENV infections and symptom onset of \<48 h; 1,500 mg or 3,000 mg balapiravir, or placebo, BID for 5 daysSafety. tolerability, pharmacokinetics, and efficacy (viral load reduction, body temperature, quality of life)Well-tolerated; no measurable reduction in viremia, NS1 antigenemia, or fever clearance time.NCT01096576;\
[@bib115]GalidesivirYFVPhase 1, randomized, double-blind, placebo-controlled study; 2 part study with 66 adult participants, ages 18 and older, hospitalized in Brazil with first onset of symptoms occurring within previous 7 days; part 1 is a dose-ranging study (3 doses), IV treatment every 12 h for 7 days, optimized dose level will be selected for part 2Safety, tolerability, pharmacokinetics, and efficacy (viral load reduction, improvement in signs and symptoms and clinical manifestations)NA; recruitingNCT03891420[^5]

The FDA-approved compounds chloroquine, ivermectin, prednisolone, and lovastatin have also been evaluated in clinical trials for the treatment of DENV infections or for their ability to relieve associated symptoms without exacerbating infectivity. These compounds were considered to be promising candidates with the potential to be fast-tracked for approval because of their known safety profiles. Unfortunately, in a majority of these clinical studies, treatment did not provide a measurable benefit or was associated with adverse events.

Unlike for flaviviruses, significant advancement has been made for HCV antiviral drug development in the last 5 -- 10 years, with recent approval of multiple direct-acting antivirals. These combination therapies, which are discussed more thoroughly in recent reviews ([@bib4]; [@bib35]; [@bib157]), have increased safety, tolerability, and efficacy, and require shorter treatment regimens compared to the previous standard of care consisting of IFN and ribavirin.

13. Considerations for Future Research {#sec13}
======================================

It is nearly impossible to halt trends that promote the geographical expansion of some flaviviruses, such as climate change, global travel, and rapidly growing urbanization ([@bib13]). Considering the paramount international health problems that are associated with some flavivirus infections, the lack of available therapeutics to treat most diseases caused by these infections, and the continued risk for the development of drug resistant strains, further development of novel antivirals for the treatment of flavivirus infections will continue to remain a priority. The dependency of *Flaviviridae* and other viruses on the host for N-linked glycosylation and glycoprotein production provides an opportunity for a host-targeted approach to broad-spectrum antiviral drug development.

While significant advances have been made in HCV antiviral drug development, most available therapies are not suitable for use in children, and there are a small percentage of adults (\<5%) that do not respond to treatment. Drug development for HCV infections is still advancing with multiple other direct-acting antivirals being developed and tested in preclinical and clinical studies. The possible emergence of drug resistant strains will continue to have to be monitored, particularly because nearly all of the approved therapies and investigational agents directly target viral proteins. While the use of drug combinations can minimize the risk of resistant strains from developing, the inclusion of a host-targeted antiviral, such as an iminosugar, in a combination cocktail could further reduce the potential for viruses to mutate and no longer respond to the approved treatment.

One of the practical challenges that needs to be considered when developing novel iminosugars as HTAVs is that, because both the virus and the host depend on ER glucosidases for glycan processing, the development of potent compounds could potentially have a negative impact on the host. Regulatory agency concerns around this issue have likely slowed development of HTAV therapies compared to direct-acting antivirals. However, good therapeutic window and high tolerability have been observed for some iminosugars in animal infection models, suggesting that viral proteins may be more susceptible to enzyme inhibition than host proteins. It is likely viral proteins are being synthesized at an exponentially higher rate compared to host proteins during the proliferative phase of an acute viral infection, which may provide a window between drug levels required to impact the virus and levels that might result in significant impact on the host. Experimentally, the unique sensitivity of M-protein to glucosidase inhibition in hepatitis B virus infected cells, demonstrated by Block et al., supports the idea that a therapeutic window can be found ([@bib11]; [@bib147]). However, replication rates and viral burden can vary both in infected individuals and for different viruses, which may require some 'tailoring' of drug dosage or schedule. Demonstrating an acceptable therapeutic window for HTAVs remains the next hurdle for approval of HTAV drug candidates by international regulatory agencies.

Further research investigating virus lifecycles and viral/host interactions could eventually lead to the identification of novel host targets for the development of HTAV to combat flavivirus infections. As with many other viruses, a combination of antivirals may be necessary to maximize the response and, as drugs become available, research providing insight into their potential synergy when used in combination with other antivirals is warranted. With continued efforts, the future provides hope for available treatment options to combat flavivirus infections caused by both known viruses and those yet to be identified.
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[^1]: Abbreviations: BVDV, bovine viral diarrhea virus; DENV, dengue virus; EC~50~, half maximal effective concentration; ER, endoplasmic reticulum; IC~50~, half maximal inhibitory concentration; IFN- α, interferon alpha; JEV, Japanese encephalitis virus; MDBK: Madin-Darby bovine kidney; MOI, multiplicity of infection; NS1, non-structural protein 1; PS, porcine stable; PFU, plaque-forming unit; prM: precursor membrane protein; prME: precursor membrane-envelope protein complex; WNV, West Nile virus; YFV, yellow fever virus

[^2]: Abbreviations: BVDV, bovine viral diarrhea virus; CC~50,~ 50% cytotoxic concentration; DENV, dengue virus; EC~50~, half maximal effective concentration; ER, endoplasmic reticulum; GBV-B, GB virus B; HCV, hepatitis C virus; IC~50~, half maximal inhibitory concentration; IFN, interferon; JEV, Japanese encephalitis virus; KUN, Kunjin virus; MDBK: Madin-Darby bovine kidney; MDM, monocyte-derived macrophages; MOI, multiplicity of infection; PS, porcine stable; PFU, plaque-forming unit; prM: precursor membrane protein; prME: precursor membrane-envelope protein complex; VLP, virus-like particle; WNV, West Nile virus; YFV, yellow fever virus; ZIKV, zika virus

[^3]: Abbreviations: BVDV, bovine viral diarrhea virus; CC~50,~ 50% cytotoxic concentration; DENV, dengue virus; EC~50~, half maximal effective concentration; HCV, hepatitis C virus; IC~50~, half maximal inhibitory concentration; IFN, interferon; JEV, Japanese encephalitis virus; MDBK: Madin-Darby bovine kidney; MDM, monocyte-derived macrophages; MOI, multiplicity of infection; PS, porcine stable; PFU, plaque-forming unit; RBV, ribavirin

[^4]: Abbreviations: BID, twice daily; DENV, dengue virus; h, hours; HCV, hepatitis C virus; IFN, interferon; NA, not available; NS1, non-structural protein 1; qd, once daily; RT-PCR, reverse transcription polymerase chain reaction; TID, three times daily; WNV, West Nile virus

[^5]: Abbreviations: BID, twice daily; DENV, dengue virus; h, hours; HCV, hepatitis C virus; IFN, interferon; NA, not available; NS1, non-structural protein 1; RT-PCR, reverse transcription polymerase chain reaction; TID, three times daily; WNV, West Nile virus; YFV, yellow fever virus
